Phase II study of oral S‐1 for treatment of metastatic colorectal carcinoma

2004116 citationsJournal Articlebronze Open Access

Authors

Kuniaki Shirao · National Cancer Center

Atsushi Ohtsu · National Cancer Center Hospital East

Hideho Takada · Kansai Medical University

Yasushi Mitachi · Sendai Shakai Hoken Hospital

Kosei Hirakawa · Osaka City University

N Horikoshi · The Cancer Institute Hospital

Takeshi Okamura

Abstract

Orally administered S-1 is active against metastatic colorectal carcinoma and has an acceptable toxicity profile. This promising agent has the potential to become a valuable chemotherapeutic option.

Topics & Keywords

Colorectal Cancer Treatments and Studies Cancer Treatment and Pharmacology Hepatocellular Carcinoma Treatment and Prognosis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer

Volume 100, Issue 11, pp. 2355-2361

DOI: 10.1002/cncr.20277

Field-Weighted Citation Impact: 3.23